Literature DB >> 27241336

Treatment and Prognosis of Pulmonary Hypertension in the Left Ventricular Assist Device Patient.

Christopher W Jensen1, Andrew B Goldstone1, Y Joseph Woo2,3.   

Abstract

This review will discuss the medical management of pulmonary hypertension in patients with left ventricular assist devices. Although much has been written on the management of primary pulmonary hypertension, also called pulmonary arterial hypertension, this review will instead focus on the treatment of pulmonary hypertension secondary to left heart disease. The relevant pharmacotherapy can be divided into medications for treating heart failure, such as diuretics and β-blockers, and medications for treating pulmonary hypertension. We also discuss important preoperative considerations in patients with pulmonary hypertension; the relationships between left ventricular assist devices, pulmonary hemodynamics, and right heart failure; as well as optimal perioperative and long-term postoperative medical management of pulmonary hypertension.

Entities:  

Keywords:  Bosentan; Left heart failure; Nitric oxide; Pulmonary hypertension; Sildenafil; Ventricular assist device

Mesh:

Year:  2016        PMID: 27241336     DOI: 10.1007/s11897-016-0288-6

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  80 in total

1.  Risk factors predictive of right ventricular failure after left ventricular assist device implantation.

Authors:  Stavros G Drakos; Lindsay Janicki; Benjamin D Horne; Abdallah G Kfoury; Bruce B Reid; Stephen Clayson; Kenneth Horton; Francois Haddad; Dean Y Li; Dale G Renlund; Patrick W Fisher
Journal:  Am J Cardiol       Date:  2010-02-13       Impact factor: 2.778

2.  Postoperative right ventricular failure after left ventricular assist device placement is predicted by preoperative echocardiographic structural, hemodynamic, and functional parameters.

Authors:  Amresh Raina; Harish Raj Seetha Rammohan; Zachary M Gertz; J Eduardo Rame; Y Joseph Woo; James N Kirkpatrick
Journal:  J Card Fail       Date:  2013-01       Impact factor: 5.712

3.  A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

Authors:  R M Califf; K F Adams; W J McKenna; M Gheorghiade; B F Uretsky; S E McNulty; H Darius; K Schulman; F Zannad; E Handberg-Thurmond; F E Harrell; W Wheeler; J Soler-Soler; K Swedberg
Journal:  Am Heart J       Date:  1997-07       Impact factor: 4.749

4.  Pulmonary hypertension predicts all-cause mortality in patients with heart failure: a retrospective cohort study.

Authors:  Benjamin R Szwejkowski; Douglas H J Elder; Fiona Shearer; David Jack; Anna Maria J Choy; Stuart D Pringle; Allan D Struthers; Jacob George; Chim C Lang
Journal:  Eur J Heart Fail       Date:  2011-12-16       Impact factor: 15.534

5.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

6.  Evolving trends in risk profiles and causes of death after heart transplantation: a ten-year multi-institutional study.

Authors:  J K Kirklin; D C Naftel; R C Bourge; D C McGiffin; J A Hill; R J Rodeheffer; B E Jaski; P J Hauptman; M Weston; C White-Williams
Journal:  J Thorac Cardiovasc Surg       Date:  2003-04       Impact factor: 5.209

7.  Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.

Authors:  Gérald Simonneau; Lewis J Rubin; Nazzareno Galiè; Robyn J Barst; Thomas R Fleming; Adaani E Frost; Peter J Engel; Mordechai R Kramer; Gary Burgess; Lorraine Collings; Nandini Cossons; Olivier Sitbon; David B Badesch
Journal:  Ann Intern Med       Date:  2008-10-21       Impact factor: 25.391

8.  Transplantation for idiopathic pulmonary arterial hypertension: improvement in the lung allocation score era.

Authors:  Justin M Schaffer; Steve K Singh; David L Joyce; Bruce A Reitz; Robert C Robbins; Roham T Zamanian; Hari R Mallidi
Journal:  Circulation       Date:  2013-05-22       Impact factor: 29.690

9.  PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support.

Authors:  Ryan J Tedford; Anna R Hemnes; Stuart D Russell; Ilan S Wittstein; Mobusher Mahmud; Ari L Zaiman; Stephen C Mathai; David R Thiemann; Paul M Hassoun; Reda E Girgis; Jonathan B Orens; Ashish S Shah; David Yuh; John V Conte; Hunter C Champion
Journal:  Circ Heart Fail       Date:  2008-11       Impact factor: 8.790

10.  Echocardiographic assessment of pulmonary artery systolic pressure and outcomes in ambulatory heart failure patients.

Authors:  Andreas P Kalogeropoulos; Sarawut Siwamogsatham; Salim Hayek; Song Li; Anjan Deka; Catherine N Marti; Vasiliki V Georgiopoulou; Javed Butler
Journal:  J Am Heart Assoc       Date:  2014-02-03       Impact factor: 5.501

View more
  2 in total

1.  Decoupling Between Diastolic Pulmonary Artery Pressure and Pulmonary Capillary Wedge Pressure as a Prognostic Factor After Continuous Flow Ventricular Assist Device Implantation.

Authors:  Teruhiko Imamura; Ben Chung; Ann Nguyen; Daniel Rodgers; Gabriel Sayer; Sirtaz Adatya; Nitasha Sarswat; Gene Kim; Jayant Raikhelkar; Takeyohi Ota; Tae Song; Colleen Juricek; Viktoriya Kagan; Valluvan Jeevanandam; Mandeep Mehra; Daniel Burkhoff; Nir Uriel
Journal:  Circ Heart Fail       Date:  2017-09       Impact factor: 8.790

Review 2.  Implication of Hemodynamic Assessment during Durable Left Ventricular Assist Device Support.

Authors:  Teruhiko Imamura; Nikhil Narang
Journal:  Medicina (Kaunas)       Date:  2020-08-15       Impact factor: 2.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.